INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $523,245 | -77.9% | 10,045 | -73.1% | 0.00% | -100.0% |
| Q2 2023 | $2,365,002 | +279.2% | 37,350 | +224.3% | 0.00% | – |
| Q1 2023 | $623,700 | +29.5% | 11,518 | +26.5% | 0.00% | – |
| Q4 2022 | $481,677 | -3.5% | 9,102 | -15.3% | 0.00% | – |
| Q3 2022 | $499,000 | -48.5% | 10,742 | -36.6% | 0.00% | -100.0% |
| Q2 2022 | $968,000 | -79.1% | 16,951 | -77.6% | 0.00% | -66.7% |
| Q1 2022 | $4,641,000 | +274.6% | 75,840 | +220.3% | 0.00% | +200.0% |
| Q4 2021 | $1,239,000 | -50.5% | 23,676 | -64.7% | 0.00% | 0.0% |
| Q3 2021 | $2,503,000 | +24.3% | 67,147 | +36.1% | 0.00% | 0.0% |
| Q2 2021 | $2,014,000 | +78.1% | 49,349 | +48.2% | 0.00% | 0.0% |
| Q1 2021 | $1,131,000 | -33.4% | 33,303 | -37.7% | 0.00% | 0.0% |
| Q4 2020 | $1,699,000 | +479.9% | 53,425 | +367.3% | 0.00% | – |
| Q3 2020 | $293,000 | -67.0% | 11,432 | -67.0% | 0.00% | -100.0% |
| Q2 2020 | $889,000 | +117.4% | 34,607 | +30.1% | 0.00% | – |
| Q1 2020 | $409,000 | -20.9% | 26,591 | +76.3% | 0.00% | – |
| Q4 2019 | $517,000 | +341.9% | 15,084 | -3.7% | 0.00% | – |
| Q3 2019 | $117,000 | -44.0% | 15,656 | -2.7% | 0.00% | – |
| Q2 2019 | $209,000 | +14.2% | 16,084 | +7.0% | 0.00% | – |
| Q1 2019 | $183,000 | -28.8% | 15,025 | -33.5% | 0.00% | – |
| Q4 2018 | $257,000 | -37.2% | 22,585 | +19.7% | 0.00% | – |
| Q3 2018 | $409,000 | +25.8% | 18,866 | +2.6% | 0.00% | – |
| Q2 2018 | $325,000 | -12.4% | 18,386 | +4.4% | 0.00% | – |
| Q1 2018 | $371,000 | +57.9% | 17,603 | +8.5% | 0.00% | – |
| Q4 2017 | $235,000 | +13.0% | 16,223 | +23.0% | 0.00% | – |
| Q3 2017 | $208,000 | -3.7% | 13,188 | -24.2% | 0.00% | – |
| Q2 2017 | $216,000 | +1.4% | 17,395 | +32.8% | 0.00% | – |
| Q1 2017 | $213,000 | -12.7% | 13,100 | -19.0% | 0.00% | – |
| Q4 2016 | $244,000 | -58.4% | 16,172 | -58.0% | 0.00% | – |
| Q3 2016 | $586,000 | -11.7% | 38,498 | +125.2% | 0.00% | -100.0% |
| Q2 2016 | $664,000 | -37.0% | 17,098 | -54.9% | 0.00% | 0.0% |
| Q1 2016 | $1,054,000 | -53.8% | 37,916 | -10.6% | 0.00% | -50.0% |
| Q4 2015 | $2,282,000 | +282.9% | 42,417 | +185.1% | 0.00% | +100.0% |
| Q3 2015 | $596,000 | +508.2% | 14,878 | +382.7% | 0.00% | – |
| Q2 2015 | $98,000 | +32.4% | 3,082 | -0.3% | 0.00% | – |
| Q1 2015 | $74,000 | -14.9% | 3,092 | -37.3% | 0.00% | – |
| Q4 2014 | $87,000 | +987.5% | 4,935 | +730.8% | 0.00% | – |
| Q3 2014 | $8,000 | +300.0% | 594 | +312.5% | 0.00% | – |
| Q2 2014 | $2,000 | – | 144 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |